Key Highlights

  • Vir Biotechnology shares slid 17.7%, reaching USD 9.98 on Friday, November 13, 2026, per market data, implying a prior close near USD 12.13 (calculated) against USD 13.13 last reported on November 11.
  • The version of the preliminary prospectus supplement reviewed, dated November 12, 2026, left the number of shares, pricing and proceeds empty for a planned common stock sale, and underwriters also hold a 30-day option.
  • The Phase 3 ECLIPSE 1 study, announced November 9, hit its primary goal: 44% of treated patients had undetectable virus and normal liver enzymes at week 48, compared with 0% of the delayed-treatment group at week 12.
  • On September 30, 2026, cash and investments totalled USD 901.3 million, the third-quarter net loss reached USD 96.3 million, and 169,414,129 shares were outstanding as of that date.

Share Offering Filed Three Days After the Trial Data

Vir Biotechnology (NASDAQ:VIR) traded 17.7% lower at USD 9.98 on Friday, November 13, 2026, per market data, a figure limited to that live session. The company released positive Phase 3 data on November 9, and published coverage put that day's gain anywhere from about 11.75% to 22%, a discrepancy that remains unresolved. On November 12, a preliminary prospectus supplement for a public offering of common stock was filed, with final terms still blank. No release disclosing the final price was located, so any tie between the decline and the share sale rests on timing alone, not on a confirmed cause.

ECLIPSE 1 Results in Chronic Hepatitis Delta

The company develops medicines built on antibodies and small interfering RNA. The ECLIPSE 1 study included 124 adults with chronic hepatitis delta, assigned in a 2 to 1 ratio to receive monthly subcutaneous injections of tobevibart and elebsiran or delayed treatment. Among treated patients, 79% had no detectable hepatitis Delta virus at week 48, compared with 0% in the delayed group, with 85% of those who had cirrhosis and 73% of those without it reaching undetectable levels. One grade 3 treatment-related adverse event occurred and no one discontinued. The company said the combination remains under regulatory review, and no filing timeline was found. Further readouts from ECLIPSE 2 and 3 are slated for the opening quarter of 2027.

Runway, Dilution Exposure and Planned Uses of Offering Cash

According to the filing, Vir Biotechnology (NASDAQ:VIR) would use offering proceeds, together with existing cash, for pre-commercial work on the hepatitis delta program, its oncology T-cell engager platform and general corporate needs. Before the raise, cash and investments of USD 901.3 million, or around USD 991 million once October proceeds from Gilead are included, were expected to fund operations into the second half of 2028. Losses in the latest quarter totalled USD 96.3 million, against USD 163.1 million twelve months prior. Without the final share count and price, the dilution figure cannot be worked out. Sales made into a sharp rally are a familiar pattern, and the danger is further downward pressure if pricing came at a discount. The company also reported progress on VIR-5500, which carries FDA Fast Track status for late-line prostate cancer, and pivotal work with Astellas is targeted for 2027.

Where Things Stand

The share sale is the most likely explanation, but that rests on timing rather than confirmation. Vir Biotechnology (NASDAQ:VIR) filed for a public stock sale on November 12, 2026, with Phase 3 data on November 9 preceding it by three days, and the final terms could not be located. Trial data were strong on virus suppression, though fresh shares dilute existing holders, and today's 17.7% decline, to USD 9.98, gives back much of the rally. Watch the final pricing, regulatory plans for hepatitis delta and the ECLIPSE 2 and 3 data expected in the first quarter of 2027.